Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.32 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.32 |
| ▸ | CTSV | O60911 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287238 | 0.79 | ALDH1A1 (0.33) | FBP1TARBP2CTSVCTSLCTSS | |
| SCHEMBL8613414 | 0.79 | IKBKB (0.38) | FBP1TARBP2MGLLALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL19119222 | 0.77 | PDE4B (0.33) | FBP1TARBP2CTSVCTSLCTSS | |
| SCHEMBL353753 | 0.74 | PLK1 (0.38) | FBP1CTSVCTSLCTSSCTSK | |
| SCHEMBL13040071 | 0.74 | BMP1 (0.36) | FBP1 | |
| SCHEMBL13962109 | 0.74 | TARBP2 (0.35) | FBP1TARBP2CTSVCTSLCTSS | |
| SCHEMBL13247707 | 0.74 | NPSR1 (0.54) | FBP1TARBP2ALDH1A1 | |
| SCHEMBL8880779 | 0.72 | GSK3B (0.35) | FBP1TARBP2CTSVCTSLCTSS | |
| SCHEMBL2200601 | 0.71 | FBP1 (0.35) | FBP1TARBP2ALDH1A1 | |
| SCHEMBL16417693 | 0.71 | MLYCD (0.36) | FBP1TARBP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3190109-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2440550-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-11-10 | — | — | US | disclosed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-9434722-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-09-06 | — | — | US | disclosed |
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| CN-101541801-A | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2009-09-23 | — | — | CN | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008099020-A1 | 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTENES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | FBP1 3608/4885TARBP2 4342/4885CTSV 2093/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | FBP1 867/4885TARBP2 4716/4885CTSV 3777/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | FBP1 3652/4885TARBP2 4303/4885CTSV 2053/4885 |
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | FBP1 1380/4885TARBP2 4205/4885CTSV 3724/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | FBP1 3608/4885TARBP2 4342/4885CTSV 2093/4885 |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | FBP1 867/4885TARBP2 4716/4885CTSV 3777/4885 |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | FBP1 3761/4885TARBP2 1232/4885CTSV 3134/4885 |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | FBP1 801/4885TARBP2 4751/4885CTSV 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.